This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

Overview

Groupers based on "Dose form intended site" that can be sufficiently defined may be included in the 763158003 |Medicinal product (product)| hierarchy.

• For example,

  • Product manufactured as oral dose form (product)

  • Product manufactured as parenteral dose form (product)

Product manufactured as <Manufactured dose form FSN> (product)

For example,

• Product manufactured as oral dose form (product)

• Product manufactured as parenteral dose form (product)

Align naming and case significance with the FSN for the concepts that are selected as the attribute value, excluding the semantic tag.

Product manufactured as <Manufactured dose form PT>

For example,

• Product manufactured as oral dose form

• Product manufactured as parenteral dose form

Align naming and case significance with the PT for the concept that is selected as the attribute value.

Synonyms are not generally created.

This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

Overview

A high-level grouper concept supports the organization of the medicinal product concepts based on disposition: 766779001 |Medicinal product categorized by disposition (product)|

Disposition is a behavior that something can exhibit (or participate in) given the appropriate context in which to do this. For example, a person may be "disposed" (or pre-disposed) to fidget in their seat when in a stressful situation such as an interview. For medicinal products, disposition behavior can be thought of as "mechanism of action" of its active ingredient substance(s): the behavior that the active ingredient substance(s) in the product exhibit when used clinically. Disposition (mechanism of action) is distinguishable from therapeutic role, which is context dependent: for example, the mechanism of action of timolol is as a beta-adrenoceptor antagonist; this action can be used therapeutically to reduce hypertension when administered in a product given orally, or to treat glaucoma when administered in a product intended to be given ophthalmically. Medicinal products can be collected together into groups based on the disposition of their active ingredient substance(s).

Disposition is a characteristic of the active ingredient substance(s) present in the Medicinal Product, therefore disposition grouping concepts are assigned (inferred) by the classifier to medicinal products and to all their descendant concepts (medicinal product form and clinical drug concepts), although in a browser such as the DailyBuild, the inferred grouping concepts will be shown on the proximal concept only (the "medicinal product containing" concept).

Figure: Inferred view of Medicinal product showing membership of a disposition grouping (carbonic anydrase inhibitor)

This section applies to grouper concepts representing a single disposition; groupers comprised of multiple dispositions are described in .

Product containing <Active ingredient PT> (product)

For example,

• Product containing histamine receptor antagonist (product)

• Product containing histamine H2 receptor antagonist (product)

Align naming and case sensitivity with the PT for the concept that is selected as the 726542003 |Has disposition (attribute)| attribute value for the substance concept used as the attribute value for the 127489000 |Has active ingredient (attribute)|.

<Active ingredient PT>-containing product

For example,

• Histamine receptor antagonist-containing product

• Histamine H2 receptor antagonist-containing product

Align naming and case significance with the PT for the concept that is selected as the 726542003 |Has disposition (attribute)| attribute value for the substance concept used as the attribute value for the 127489000 |Has active ingredient (attribute)|.

Synonyms matching the FSN are not required.

This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

A grouper is a concept designed to aggregate concepts based on specific characteristics or commonalities. Medicinal products and their representations in a terminology can be put into groups in many ways, both in terms of abstraction and aggregation of product descriptions. In the SNOMED CT medicinal product model, the following grouping concepts will be used:

• Groupings based on the pharmaceutical characteristics of manufactured medicinal products, and the primary subject of this model and documentation: in each of the sections below, these various model classes and their attributes are defined, described in detail and diagrams provided. In addition, their relationship to IDMP is described and a note as to their population status within the upcoming releases of SNOMED CT is provided.

  • Medicinal product - grouping based on active ingredient substance(s)

  • Medicinal product form - grouping based on active ingredient substance(s) combined with a grouping of the site of administration of manufactured dose form (parenteral dose forms, oral dose forms etc.)

    • These concepts are also grouped using the site of administration of manufactured dose form as a grouping concept

  • Clinical drug - a grouping based on active ingredient substance(s), with their strength, combined with manufactured dose form

• Groupings based on the structural or behavioural characteristics exhibited by the active substance(s) that the products contain:

  • Disposition - grouping based on mechanism of action of the active ingredient substance(s) in the product

  • Structure - grouping based on structural patterns of the active ingredient substance(s) in the product

  • Structure and Disposition - combination of the above

This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

Overview

Groupers comprised of two or more existing disposition and/or structure groupers that can be sufficiently defined may be included in the |Medicinal product| hierarchy. High-level grouper concepts support the organization of the combined groupers based on disposition and/or structure:

• 766779001 |Medicinal product categorized by disposition (product)|

• 763760008 |Medicinal product categorized by structure (product)|

For some medicinal products, their clinical usefulness is related to the combination of both their structure and their disposition; it is the structure that produces the disposition.

For example,

• Clemastine is a substance whose anti-histamine behavior is based upon its structure being ethanolamine derived.

Since structure-based grouping and disposition are characteristics of the active ingredient substance(s) present in the medicinal product, combined 'structure and disposition grouping' concepts are inferred by the classifier to medicinal products and include all their child concepts (medicinal product form and clinical drug concepts), although in a browser, the inferred grouping concepts are shown on the proximal concept only (the "medicinal product containing" concept).

Figure: Medicinal Product showing membership of a structure-and-disposition grouping (ethanolamine derivative and histamine receptor antagonist)

Use the following pattern for the FSN if the combined grouper is comprised of two dispositions or two structural groupers; align naming and case significance with the PT as described in Groupers Based on Structure and Disposition, respectively. The active ingredients must be in alphabetical order and separated by the word “and”.

• Product containing <Active ingredient PT> and <Active ingredient PT> (product)

  • For example,

    • Product containing norepinephrine reuptake inhibitor and serotonin reuptake inhibitor (product)

Use the following pattern for the FSN if the combined grouper is comprised of one disposition and one structural grouper; align naming and case significance with the FSN for the concept with the FSN as described in Groupers Based on Structure and Disposition, respectively.

• Product containing <Structural grouper active ingredient PT> and <Disposition grouper active ingredient PT> (product)

  • For example,

    • Product containing piperazine derivative and histamine receptor antagonist (product)

Use the following pattern for the FSN if the combined grouper is comprised of two dispositions or two structural groupers; align naming and case significance with the PT as described in Groupers Based on Structure and Disposition, respectively. The active ingredients must be in alphabetical order and separated by the word “and”.

• Product containing <Active ingredient PT> and <Active ingredient PT> (product)

  • For example,

    • Product containing norepinephrine reuptake inhibitor and serotonin reuptake inhibitor (product)

Use the following pattern for the FSN if the combined grouper is comprised of one disposition and one structural grouper; align naming and case significance with the FSN for the concept with the FSN as described in Groupers Based on Structure and Disposition, respectively.

• Product containing <Structural grouper active ingredient PT> and <Disposition grouper active ingredient PT> (product)

  • For example,

    • Product containing piperazine derivative and histamine receptor antagonist (product)

Synonyms matching the FSN are not required.

This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

Overview

A high-level grouper concept supports the organization of the hierarchy based on structure: 763760008 |Medicinal product categorized by structure (product)|

All substances have spatial arrangement of the atoms and molecules and bonds that they are constituted from and which therefore govern the final shape that the substance takes; this arrangement is their "structure". Substance structures often follow patterns so that similar structures are grouped together and often share particular name patterns. Medicinal products can be collected together into groups based on the structural pattern(s) of their active ingredient substance(s).

Structure-based grouping is a characteristic of the active ingredient substance(s) present in the medicinal product, therefore structure-based grouping concepts are assigned (inferred) by the classifier to medicinal products and include all their child concepts (medicinal product form and clinical drug concepts) although in a browser such as the DailyBuild, the inferred grouping concepts will be shown on the proximal concept only (the "medicinal product containing" concept).

Inferred view of Medicinal product showing membership of a structural grouping (sulfonamide)

Modeling

Product containing <active ingredient> (product)

Align naming and case sensitivity with the Preferred Term for the concept that is selected as the attribute value for the 127489000 |Has active ingredient (attribute)|.

For example,

• Product containing prostaglandin (product)

• Product containing A series prostaglandin (product)

<Active ingredient>-containing product

Align naming and case significance with the Preferred Term for the concept that is selected as the attribute value.

For example,

• Prostaglandin-containing product

• A series prostaglandin-containing product

Synonyms matching the FSN are not required.

This Editorial Guide is used for Education Purposes Only. It is used in the Authoring Courses and Certifications. It is based on the January 2026 Editorial Guide.

Pharmaceutical dose form grouper concepts specifying "infusion and/or injection" are modeled using General Concept Inclusions (GCIs).

• For example,

  • 1208958005 |Conventional release solution for infusion and/or injection (dose form)|

  • 1236769008 |Gas for conventional release dispersion for infusion and/or injection (dose form)|

  • 1237269000 |Concentrate for conventional release solution for infusion and/or injection (dose form)|

The following are out of scope for the international release but can be added to national extensions, concepts that specify:

• "infusion or injection"

• "infusion and injection"

Clinical drugs modeled using pharmaceutical dose form groupers for “infusion and/or injection” are in scope for the International Release.

For example,

1252729004 |Product containing precisely ofloxacin 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug)| is modeled with |Has manufactured dose form (attribute)| of |Conventional release solution for infusion and/or injection (dose form)|.

In cases where corresponding clinical drugs for both injection and infusion exist, the grouper for “infusion and/or injection” should be created. In other words, when creating a new clinical drug for infusion and an existing injection concept exists with the same substance and strength, then the grouper "for infusion and/or injection" should be created.

For example,